Drug Type Monoclonal antibody |
Synonyms 611, SSGJ-611 |
Target |
Action inhibitors |
Mechanism IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pulmonary Disease, Chronic Obstructive | Phase 3 | China | 09 Jun 2025 | |
Nasal Polyps | Phase 3 | China | 01 Nov 2024 | |
Chronic rhinosinusitis with nasal polyps | Phase 3 | China | 10 Oct 2024 | |
Moderate Atopic Dermatitis | Phase 3 | China | 11 Jan 2024 | |
Severe Atopic Dermatitis | Phase 3 | China | 11 Jan 2024 | |
Dermatitis, Atopic | Phase 2 | United States | - | |
Autoimmune Diseases | Phase 1 | United States | 30 Jan 2022 | |
Autoimmune Diseases | Phase 1 | China | 30 Jan 2022 |
Phase 2 | Moderate Atopic Dermatitis serum thymus activation-regulated chemokine (TARC) | total serum immunoglobulin E (IgE) | - | 611 300 mg every 2 weeks | ueljfeyzqq(dehmjgoqek) = ceubkuyilp izgcxtlijc (dogtpbfkvr ) | Positive | 09 Mar 2025 | |
611 300 mg every 4 weeks | ueljfeyzqq(dehmjgoqek) = rmcsqfovlp izgcxtlijc (dogtpbfkvr ) | ||||||
NCT05865496 (NEWS) Manual | Phase 2 | - | 611 300mg Q2W | rwharryoso(dhlvivewlg) = tiztxdscqp kjsigfrgfm (srmduqipvy ) Met View more | Positive | 10 Aug 2024 | |
611 450mg Q4W | rwharryoso(dhlvivewlg) = cyjlsmelmo kjsigfrgfm (srmduqipvy ) Met View more | ||||||
NCT05544591 (NEWS) Manual | Phase 2 | 93 | 611 首剂600 mg + 300 mg Q2W | yjlgcujsqm(fyvabzxhkp) = eltmvzpnrj ynmzwxvyri (eilffzyobn ) View more | Positive | 22 Aug 2023 | |
611 首剂600 mg + 300 mg Q2W | yjlgcujsqm(fyvabzxhkp) = sshjkbndgy ynmzwxvyri (eilffzyobn ) View more |